Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2021-02-17 Capital/Financing Update
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
Consent letter of underwriters' legal counsel.pdf
Capital/Financing Update Classification · 90% confidence The document is a letter from a law firm providing consent related to a short form prospectus dated February 17, 2021. It references the prospectus and confirms no misrepresentations in the information derived from their opinion. The document is short (1794 characters) and does not contain financial data or detailed report content. It is an announcement or confirmation related to a financing document (prospectus) rather than the prospectus itself or a financial report. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-02-17 English
Final short form prospectus – English.pdf
Capital/Financing Update Classification · 100% confidence The document is a short form prospectus for a public offering of securities by Medexus Pharmaceuticals Inc. It details the offering price, number of units, underwriting agreement, listing information, and terms of the securities being offered. The text includes legal disclaimers about securities registration and distribution, underwriting fees, over-allotment options, and broker warrants. This type of document is a formal offering prospectus related to capital raising activities, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or regulatory filing but a substantive financing document.
2021-02-17 English
Undertaking to file documents and material contracts.pdf
Regulatory Filings Classification · 95% confidence The document is an undertaking addressed to multiple Canadian securities commissions regarding a Short Form Prospectus dated February 17, 2021. It references National Instrument 44-101 and 51-102, which govern continuous disclosure obligations and prospectus distributions. The text commits to filing material contracts and agreements related to securities distributions under the Prospectus. The document is a regulatory undertaking related to securities filings rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is short (2379 characters) and is primarily a formal regulatory compliance statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2021-02-17 English
Final short form prospectus – French.pdf
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus for a new issuance of securities by Medexus Pharmaceuticals Inc., describing the offering of units consisting of ordinary shares and warrants, pricing, underwriting arrangements, and regulatory compliance. It includes detailed terms of the offering, subscription rights, and conditions of sale. This type of document is a formal offering prospectus related to capital raising activities, which fits the category of Capital/Financing Update filings. It is not an annual or interim report, audit report, earnings release, or any other category. The document is lengthy and substantive, not a mere announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-02-17 English
Non-issuer's submission to jurisdiction and appointment of agent.pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Non-Issuer Form of Submission to Jurisdiction and Appointment of Agent for Service of Process' and references National Instrument 41-101, which relates to prospectus requirements and securities distribution. It contains details about the issuer, filing person, agent for service of process, and legal jurisdiction for proceedings related to securities distribution. There are no financial statements, earnings data, or management discussion. The document is a regulatory filing related to legal and procedural compliance for securities distribution, not a financial report or announcement of voting results, management changes, or capital updates. It fits best under Regulatory Filings (RNS) as a compliance document that does not fit other specific categories.
2021-02-17 English
Auditors' consent letter.pdf
Regulatory Filings Classification · 95% confidence The document text is very short (2525 characters) and appears to be heavily redacted or encoded, with no clear financial data, report content, or detailed analysis. It contains references to codes and some cryptic text but lacks substantive financial statements or management discussion. There is no indication that this is a full report such as an Annual Report (10-K) or Interim Report (IR). The text does not resemble a call transcript, earnings release, or any detailed presentation. Given the length and nature, it is likely an announcement or a regulatory filing of some sort, possibly a certification or a brief notice. According to the rules, if a document is short and does not contain actual financial data, it should be classified as Regulatory Filings (RNS).
2021-02-17 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.